Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized, placebo- and tolterodine-controlled study of MK-4618 in overactive bladder
KCT0000316Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vibegron in overactive bladder (OAB), sponsored by Merck & Co.. Started Jun 2011; status: recruiting.
02
Drugs
vibegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on KCT0000316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000316.